Loading...
Market
What policy changes will occur for obesity drugs under Makary's FDA leadership by end of 2025?
2
Resolution / Starting Odds
Stricter Regulations • 25%
Looser Regulations • 25%
No Change • 25%
New Initiatives • 25%
Official FDA policy announcements
Story
Trump Nominates Marty Makary to Lead FDA; $1.5 Billion Sesamecare's Weight-Loss Drug Role in Focus
Nov 24, 2024, 09:39 PM
Marty Makary, a member of the board of directors of a $1.5 billion pharmaceutical company, has been officially nominated by President Trump to head the FDA. Makary is also the Chief Medical Officer for Sesamecare, a telehealth company that promotes compounded semaglutide, a weight-loss drug. His nomination intersects with obesity policy, raising concerns about the revolving door between industry and government. If confirmed as FDA commissioner, Makary would lead the FDA as it deals with high-stakes policy issues that could impact Sesamecare's business.
View original story
Similar markets
Yes • 50%
No • 50%
Healthcare Transparency • 25%
Chronic Disease Management • 25%
Pandemic Response • 25%
Drug Approval Process • 25%
Chronic Disease Management • 25%
Vaccine Policy • 25%
Drug Approval Process • 25%
Medical Device Regulation • 25%
Yes • 50%
No • 50%
Confirmed • 33%
Rejected • 33%
Withdrawn • 34%
Stricter regulations • 25%
Looser regulations • 25%
No change • 25%
Ban on certain drugs • 25%
Drug pricing reform • 25%
Streamlining drug approval process • 25%
Vaccine distribution strategy • 25%
Other • 25%
Approved as proposed • 25%
Approved with modifications • 25%
Rejected • 25%
No decision by deadline • 25%